Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-06-30

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety and tolerability of XL147 in subjects with solid tumors or lymphoma. Both a capsule and a tablet formulation will be evaluated. XL147 is a new chemical entity that inhibits PI3 Kinase. Inactivation of PI3K has been shown to inhibit growth and induce apoptosis (programmed cell death) in tumor cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

NCT05144347

Non-Hodgkin's Lymphoma (NHL) Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC-DLBCL) Mantle Cell Lymphoma (MCL) +2 more

TERMINATED PHASE1

Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma

NCT00536835

Lymphoma, Non-Hodgkin

COMPLETED PHASE1

Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors

NCT00100347

Non-Hodgkin's Lymphoma, Solid Tumors

TERMINATED PHASE1

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

NCT01703481

Tumor or Lymphoma

COMPLETED PHASE1

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

NCT05487170

Advanced Solid Tumor DLBCL

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Daily dosing for 21 days/7 days off

Group Type EXPERIMENTAL

XL147 (SAR245408)

Intervention Type DRUG

Gelatin capsules supplied in 25-mg and 100-mg dosage strengths

2

Continuous daily dosing

Group Type EXPERIMENTAL

XL147 (SAR245408)

Intervention Type DRUG

Gelatin capsules supplied in 25-mg and 100-mg dosage strengths

3

Continuous daily dosing

Group Type EXPERIMENTAL

XL147 (SAR245408)

Intervention Type DRUG

Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

XL147 (SAR245408)

Gelatin capsules supplied in 25-mg and 100-mg dosage strengths

Intervention Type DRUG

XL147 (SAR245408)

Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject has a histologically confirmed solid tumor that is metastatic or unresectable, and for which standard curative or palliative measures do not exist or are no longer effective, and there are no known therapies to prolong survival. An expanded cohort will be enrolled; NSCLC subjects enrolled must have a diagnosis of relapsed or refractory NSCLC (Stage IIIB or IV) and have received at least two prior regimens including one platinum-based chemotherapy regimen.
2. The subject has a histologically confirmed diagnosis of lymphoma which is relapsed or refractory to standard therapy.
3. For subjects with solid tumors, the subject has disease that is assessable by tumor marker, physical, or radiologic means. There are separate criteria that apply to subjects with lymphoma.
4. Subjects with indolent lymphoma must have documented disease status within 12 months prior to study entry.
5. The subject is ≥18 years old.
6. The subject's weight is ≥40 kg.
7. The subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
8. The subject has adequate organ and marrow function, and a fasting plasma glucose (FPG) \<160 mg/dL and HbA1c of \<8% at screening.
9. For the subjects with solid tumors who are to be enrolled into the expanded MTD cohort and tumor genetic alteration subjects:

1. tumor tissue amenable to serial biopsy, and
2. additional informed consent.
10. The subject is capable of understanding and complying with the protocol and has signed the informed consent document.
11. Sexually active subjects (male and female) must use medically acceptable methods of contraception during the course of the study and for 3 months following discontinuation of study drug.
12. Female subjects of childbearing potential must have a negative serum pregnancy test at screening.
13. At least ten 4-10 micron tissue sections, archival or fresh, or a tissue block, of the subject's tumor should be identified and designated for shipment to the sponsor where allowed by local regulatory bodies. For subjects with lymphoma, tissue from an excisional or core biopsy or, in case of marrow involvement, a bone marrow aspirate/biopsy is acceptable.

Exclusion Criteria

1. The subject has previously been treated with a selective PI3K inhibitor.
2. Additional restrictions on prior treatment apply.
3. For lymphoma subjects: known central nervous system involvement, autoimmune disease requiring immunosuppressive therapy, systemic treatment with prednisone \>20mg/day or equivalent within 2 weeks prior to first dose of XL147, autologous stem cell transplantation within 12 weeks prior to first dose, history of any allogeneic transplantation.
4. The subject has not recovered from toxicity due to all prior therapies.
5. The subject has a primary brain tumor. Subjects with brain metastasis are considered eligible if the subject has not received radiation therapy for brain metastasis within 2 weeks of enrollment and has been on a stable dose of steroids for 2 or more weeks.
6. The subject is currently receiving anticoagulation with therapeutic doses of warfarin (low-dose warfarin is permitted).
7. The subject has prothrombin time/partial thromboplastin time (PT/PTT) or International Normalized Ratio (INR) test results at screening that are above 1.3x the laboratory upper limit of normal.
8. The subject has an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
9. The subject has psychiatric illness/social situation(s) that would limit compliance with study requirements.
10. The subject is pregnant or breastfeeding.
11. The subject is known to be positive for the human immunodeficiency virus (HIV).
12. The subject has a previously identified allergy or hypersensitivity to components of the XL147 formulation.
13. The subject has a baseline corrected QT interval (QTc) \>460 ms.
14. The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No